麗珠集團(000513.SZ):注射用雙羥萘酸曲普瑞林微球獲批臨牀試驗
格隆匯 4 月 7日丨麗珠集團(000513.SZ)公佈,近日,公司及全資附屬公司珠海市麗珠微球科技有限公司(“麗珠微球”)收到國家藥品監督管理局(“藥監局”)核准簽發的《藥物臨牀試驗批准通知書》,藥物名稱為注射用雙羥萘酸曲普瑞林微球。
注射用雙羥萘酸曲普瑞林微球歷經6年研發,是公司自主開發的高端長效微球製劑,首次提交臨牀試驗申請獲得受理的時間為2021年01月20日(受理號:CXHL2100048)。
本產品是每三月一次肌肉注射的一種促性腺激素釋放激素激動劑,適應症為局部晚期或轉移性前列腺癌的治療。相比普通曲普瑞林注射劑,具有起效時間長,減少用藥次數特點,可減輕患者痛苦和用藥負擔,提高用藥耐受性和可及性。
截至公吿日,注射用雙羥萘酸曲普瑞林微球累計直接投入的研發費用約人民幣1499.45萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.